AstraZeneca stock dives 9% after heart drug trial misses target

shares AstraZeneca It fell as low as 9 percent after a late-stage clinical trial for an experimental heart disease treatment failed to meet its target.

The drug Wainua did this failing to achieve one’s main goal It reduced deaths and recurrent heart-related emergencies over 140 weeks compared to placebo, the British drugmaker said in a press release early Thursday.

The treatment is for a rare, life-threatening heart condition called transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

The stock was last seen losing 8.9% in London, heading for its worst day since the Covid-19 pandemic began in March 2020.

This is breaking news. Please refresh for updates.